FDA Approved: TRAZIMERA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approved Pfizer's supplemental Biologics License Application for TRAZIMERA (trastuzumab-qyyP), a biosimilar to trastuzumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• TRAZIMERA (TRASTUZUMAB-QYYP)

Snippet

SUPPL AP for TRAZIMERA (TRASTUZUMAB-QYYP)